ESTRING (estradiol) by Pfizer is estrogen receptor agonists [moa]. First approved in 1996.
Drug data last refreshed 14h ago · AI intelligence enriched 17h ago
ESTRING is a vaginal estradiol insert approved in 1996 that delivers estrogen directly to vaginal tissue via extended-release formulation. It works as an estrogen receptor agonist to treat vaginal atrophy and related menopausal symptoms. The localized delivery minimizes systemic exposure while providing sustained hormone replacement.
Product approaching loss of exclusivity with moderate Medicare spending signals defensive positioning and smaller brand teams focused on market maintenance.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on ESTRING at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moESTRING offers limited new career opportunities with zero linked job openings, reflecting a mature product in defensive phase. Roles available focus on protecting market share, managing reimbursement challenges, and optimizing sales efficiency rather than driving growth or innovation.